Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (393)	6/5/2003 2:47:53 PM
From: Icebrg	Read Replies (1) \| Respond to of 1840

Lung Cancer Study Could Change Standard of Care Charlene Laino June 3, 2003 (Chicago) — In a finding that some oncologists say could change the standard of care for patients with resected non-small cell lung cancer (NSCLC), an international trial has shown for the first time that patients treated with cisplatin-based chemotherapy after surgery are significantly more likely to be alive five years later than those given surgery alone. The 4.1% 5-year survival advantage conferred by adjuvant chemotherapy in NSCLS patients is slightly smaller than the 5% to 20% survival benefit, depending on the stage of disease, associated with giving chemotherapy after surgery to patients with breast and colon cancer... medscape.com